NCT01190982 - Efficacy and Safety Study of LEP-ETU to Treat Metastatic Breast Cancer | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2008

Primary Completion Date

December 31, 2011

Study Completion Date

December 31, 2011

Conditions

Breast Cancer

Interventions

DRUG

LEP-ETU

275 mg/m2, IV (in the vein) on day 1 of each 21 day cycle, 6 Cycles or until progression or unacceptable toxicity develops.

Trial Locations (3)

Indo-American Cancer Institute and Research Center, Banjara Hills

P.D. Hinduja Antional Hospital & Medical Research Center, Mahīm

Jaslok Hospital and Research Center, Mumbai